Patents Issued in March 9, 2021
  • Nano-encapsulation using GRAS materials and applications thereof
    Patent number: 10940119
    Abstract: In one aspect, methods of preparing composite nanoparticle compositions are described herein. For example, in some embodiments, a method comprises providing a zein solution stream, an organic fluid stream including at least one additive and at least one buffer fluid stream. The zein solution stream, organic fluid stream and buffer fluid stream are delivered to a chamber for mixing at one or more rates sufficient to flash precipitate composite nanoparticles including the additive encapsulated by a shell comprising the zein.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: March 9, 2021
    Assignee: The Trustees of Princeton University
    Inventors: Nikolas T. Weissmueller, Robert K. Prud'Homme
  • Methods and compositions for wound healing
    Patent number: 10940120
    Abstract: The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polymers to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: March 9, 2021
    Assignee: IMBED BIOSCIENCES, INC.
    Inventors: Jonathan F. McAnulty, Christopher Murphy, Nicholas Abbott
  • Gel patch
    Patent number: 10940121
    Abstract: A method for producing a gel patch comprising an adhesive mass layer on a backing fabric, comprising a step of applying a composition comprising a physiologically active substance, a water-soluble polymer, glycerin, and water to the backing fabric to form the adhesive mass layer, wherein a loss tangent of the composition in dynamic viscoelasticity measurement at 1 Hz at a time of application to the backing fabric is 0.75 to 1.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: March 9, 2021
    Assignee: HISAMITSU PHARMACEUTICAL CO., INC.
    Inventors: Seiichiro Tsuru, Masayoshi Maki
  • Transdermal therapeutic system with fentanyl or related substances
    Patent number: 10940122
    Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 9, 2021
    Assignee: LTS LOHMANN THERAPIE-SYSTEME AG
    Inventors: Walter Müller, Thomas Hille
  • Methods and compositions for preventing or treating calciphylaxis
    Patent number: 10940123
    Abstract: The invention provides methods and compositions for preventing or treating (e.g., slowing the progression of, arresting, and/or reversing) calciphylaxis in a subject in need thereof and, more particularly, the invention relates to methods of using menaquinone-7 (MK-7) and/or menaquinol-7 (MKH2-7) for preventing or treating calciphylaxis in a subject with one or more of the following: diabetes, chronic kidney disease, end stage renal failure, and COPD or a subject undergoing hemodialysis and/or receiving anticoagulant therapy and/or statin therapy.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: March 9, 2021
    Assignee: Epizon Pharma, Inc.
    Inventors: James A. Tumlin, Paul L. Darke, John M. Rudey
  • Bupropion as a modulator of drug activity
    Patent number: 10940124
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: March 9, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Methods and compositions for the treatment of steatosis-associated disorders
    Patent number: 10940125
    Abstract: The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD la, GSD lb, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: March 9, 2021
    Assignees: DUKE UNIVERSITY, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Dwight D. Koeberl, Paul M. Yen, Benjamin L. Farah
  • Inhibition of IL-8 in the treatment of pain and/or bone loss
    Patent number: 10940126
    Abstract: Pain associated with a contribution of IL-8 and osteoclasts in a subject is prevented, treated and/or alleviated by the administration of an effective amount of a compound capable of inhibiting or blocking the action of interleukin 8 (IL-8). Methods and compounds for this use are disclosed, as well as a diagnostic method and kit.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: March 9, 2021
    Inventors: Camilla Svensson, Lars Klareskog, Vivianne Malmstrom, Anca Catrina
  • Use of CYP26-resistant RAR alpha selective agonists in the treatment of cancer
    Patent number: 10940127
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 9, 2021
    Assignees: Io Therapeutics, Inc., The Johns Hopkins University
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
    Patent number: 10940128
    Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 9, 2021
    Assignee: CYDEX PHARMACEUTICALS, INC.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Method of treatment for reducing pain sensitization
    Patent number: 10940129
    Abstract: The present disclosure relates to the use of lipophilic mercaptans for the treatment of pain sensitization. The lipophilic mercaptans disclosed can be used to decrease the formation of protein-aldehyde adducts within nociceptive nerves, thereby reducing sensitization to pain.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: March 9, 2021
    Inventor: David Michael Ott
  • Compositions comprising theanine and whey protein
    Patent number: 10940130
    Abstract: An anxiolytic composition includes a synergistic combination of an L-theanine and a whey protein composition.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 9, 2021
    Assignee: NUTRAMAX LABORATORIES, INC.
    Inventors: Todd Henderson, David Griffin, David Bledsoe
  • Methods of treating mixed dyslipidemia
    Patent number: 10940131
    Abstract: The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 9, 2021
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • CCL5 inhibitors
    Patent number: 10940132
    Abstract: Compounds, pharmaceutically acceptable salts, esters, prodrugs, and pharmaceutical compositions thereof are disclosed that are useful for inhibition of the biological activity of CCL5 on mammalian cells, as well as methods of treatment for diseases involving the increased biological activity of CCL5.
    Type: Grant
    Filed: December 21, 2019
    Date of Patent: March 9, 2021
    Assignee: AFECTA PHARMACEUTICALS, INC.
    Inventor: Bruce Kovacs
  • Methods of providing solriamfetol therapy to subjects with impaired renal function
    Patent number: 10940133
    Abstract: The invention relates to methods for decreasing adverse effects associated with solriamfetol ([R]-2-amino-3-phenylpropylcarbamate) therapy in subjects with impaired renal function. In particular, the invention provides an optimized dose escalation scheme for subjects with moderate renal impairment which results in the subjects having increased tolerance to adverse effects associated with the administration of solriamfetol. The invention also provides adjusted dosing for safe therapeutic use of solriamfetol in subjects having severe renal impairment.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: March 9, 2021
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Katayoun Zomorodi
  • Bicyclic compound and use thereof for medical purposes
    Patent number: 10940134
    Abstract: Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: March 9, 2021
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tohru Kambe, Toru Maruyama, Shinsaku Yamane, Satoshi Nakayama, Kousuke Tani
  • Paclitaxel pharmaceutical composition and pharmaceutical preparation thereof, preparation process and use thereof
    Patent number: 10940135
    Abstract: A paclitaxel pharmaceutic composition and a pharmaceutic preparation, a preparation process therefor and use thereof are provided. The paclitaxel composition contains paclitaxel as an active ingredient and hydroxypropyl methyl cellulose derivative as a carrier material. The paclitaxel preparation is in the form of an oral solid preparation. The paclitaxel composition and pharmaceutic preparation thereof can be used for the preparation of a drug for preventing and treating malignancies and relevant diseases in mammals.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: March 9, 2021
    Assignee: SINOTHERAPEUTICS INC.
    Inventors: Jiansheng Wan, Yun Fang, Kun Li
  • Cannabinoids for prophylactic treatment of involuntary weight loss
    Patent number: 10940136
    Abstract: The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prior to chemotherapy and is maintained for at least the duration of the chemotherapy.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: March 9, 2021
    Assignee: AOP ORPHAN PHARMACEUTICALS AG
    Inventors: Agnes Kohl, Ralf Lenhard
  • Materials and methods for improving gastrointestinal function
    Patent number: 10940137
    Abstract: The subject invention provides therapeutic compositions, and uses thereof for the treatment or amelioration of injury to small intestine mucosa. In preferred embodiments, the composition comprises one or more nutrients and/or electrolytes that acquire or retain considerable absorptive capacity.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: March 9, 2021
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Sadasivan Vidyasagar, Paul Okunieff, Lurong Zhang
  • Compositions and methods for treating ocular disorders
    Patent number: 10940138
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: March 9, 2021
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
    Patent number: 10940139
    Abstract: Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
    Type: Grant
    Filed: October 16, 2019
    Date of Patent: March 9, 2021
    Assignee: Shy Therapeutics LLC
    Inventors: Yaron R. Hadari, Luca Carta, Michael Schmertzler, Theresa M. Williams, Charles H. Reynolds, Rebecca Hutcheson
  • Pharmaceutical composition for the treatment of autism
    Patent number: 10940140
    Abstract: The present invention relates to a pharmaceutical composition or a kit comprising, a first substance capable of raising intracellular cAMP levels, and a second substance capable of modulating intracellular calcium concentration. Likewise, the present invention relates to methods of treating patients suffering from autism spectrum disorder (ASD) phenotype 1 by administering an effective amount of a substance capable of raising intracellular cAMP levels and, optionally, an effective amount of a substance capable of modulating intracellular calcium concentration.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: March 9, 2021
    Assignee: Stalicla S.A.
    Inventor: Lynn Durham
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10940141
    Abstract: Provided is a method of administering a vesicular monoamine transporter 2 (VMAT2) inhibitor to a subject in need thereof, wherein the subject has severe renal impairment.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: March 9, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Gordon Raphael Loewen, Sha Rosa Luo
  • Inhibition of crystal growth of roflumilast
    Patent number: 10940142
    Abstract: Roflumilast crystals have been shown to increase in size during storage. The size of the roflumilast crystals can affect the bioavailability and efficacy of a pharmaceutical composition. The growth of roflumilast crystals can be inhibited during storage by including hexylene glycol in the composition. The resulting composition has improved bioavailability and efficacy and can be used to inhibit phosphodiesterase 4 in a patient in need of such treatment.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: March 9, 2021
    Assignee: Arcutis, Inc.
    Inventor: David W. Osborne
  • Deuterium-enriched pioglitazone
    Patent number: 10940143
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 9, 2021
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • Drug containing pyridylaminoacetic acid compound
    Patent number: 10940144
    Abstract: The present invention aims to find a novel pharmaceutical use of omidenepag, esters thereof, or salts thereof. The present inventors have made intensive studies to find a novel pharmaceutical use of omidenepag, an ester thereof, or a salt thereof, and have found as a result that omidenepag, an ester thereof, or a salt thereof significantly dilates retinal blood vessels, and significantly increases blood flow. Therefore, omidenepag, an ester thereof, or a salt thereof is expected to protect retinal nerve cells and be useful for prevention and/or treatment of ophthalmic diseases involving retinal nerve cell disorder.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 9, 2021
    Assignee: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Takazumi Taniguchi, Takahiro Akaishi, Hitoshi Nakazawa
  • Ophthalmic composition
    Patent number: 10940145
    Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: March 9, 2021
    Assignee: SYDNEXIS, INC.
    Inventors: Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
  • NHE3-binding compounds and methods for inhibiting phosphate transport
    Patent number: 10940146
    Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: March 9, 2021
    Assignee: Ardelyx, Inc.
    Inventors: Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
  • Early treatment of CMT disease
    Patent number: 10940147
    Abstract: The present invention provides methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A), by administering to a subject in need thereof a combination comprising baclofen, sorbitol and naltrexone, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: March 9, 2021
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Rodolphe Hajj, Aude Milet, Serguei Nabirochkin, Klaus-Armin Nave, Thomas Prukop, Michael Sereda
  • Combination therapy with glutaminase inhibitors and immuno-oncology agents
    Patent number: 10940148
    Abstract: The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: March 9, 2021
    Assignee: Calithera Biosciences, Inc.
    Inventors: Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
  • Kinase inhibitor salts and compositions thereof
    Patent number: 10940149
    Abstract: The present invention relates to polymorphic forms of nilotinib lauryl sulfate salt.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 9, 2021
    Assignee: HANDA ONCOLOGY, LLC
    Inventors: Fang-Yu Liu, K. C. Sung, Chin-Yao Yang, Chi-Cheng Lin, Yi-Hsin Lin, Li Qiao
  • Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27
    Patent number: 10940150
    Abstract: The present invention relates to novel HSP27 inhibitors, in particular thymine derivatives according to general formula (VI), (VII) or (VII) and phenothiazine derivatives according to formula (V), and to their use as drugs for the selective inhibition of the heat shock protein HSP27 (HSPB1), in particular for use in the treatment of carcinomas or cystic fibrosis, said inhibitors having a particularly advantageous activity in the lower micromolar or sub-micromolar active ingredient concentration range with respect to HSP27.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: March 9, 2021
    Assignee: Technische Universitaet Dresden
    Inventors: Michael Schroeder, Yixin Zhang, Joerg-Christian Heinrich, Joachim Haupt, Sainitin Donakonda, Petra Lennig
  • Methods for treating renal disease
    Patent number: 10940151
    Abstract: The invention features methods for treating or reducing the likelihood of developing a renal disease by administering to a subject in need thereof an agent that decreases expression of a pathogenic APOL1. The agents of the method target various signaling pathways and decrease the level of the pathogenic APOL1 polypeptide.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: March 9, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David J. Friedman, Martin R. Pollak
  • Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
    Patent number: 10940152
    Abstract: Provided herein are Aminopurine Compounds having the following structures: wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing a cancer, for example, melanoma.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: March 9, 2021
    Assignee: SIGNAL PHARMACEUTICALS, LLC
    Inventors: Matthew Alexander, Sogole Bahmanyar, John Frederick Boylan, Joshua Hansen, Dehua Huang, Robert Hubbard, Brandon Jeffy, Jim Leisten, Mehran Moghaddam, Raj K. Raheja, Heather Raymon, Kimberly Schwarz, Marianne Sloss, Eduardo Torres, Tam Minh Tran, Shuichan Xu, JingJing Zhao
  • Pharmaceutical compositions comprising meloxicam
    Patent number: 10940153
    Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: March 9, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Heterocyclic amides as kinase inhibitors
    Patent number: 10940154
    Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: March 9, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jae U. Jeong, Deepak Bandyopadhyay, Patrick M. Eidam, Philip Anthony Harris, Jianxing Kang, Bryan Wayne King, Ami Lakdawala Shah, Lara Kathryn Leister, Attiq Rahman, Joshi M. Ramanjulu, Clark A. Sehon, Robert Singhaus, Jr., Daohua Zhang
  • Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
    Patent number: 10940155
    Abstract: A quetiapine fumarate composition for oral administration is provided comprising a pharmaceutically acceptable salt or solvate of quetiapine existing as a suspension in an aqueous carrier agent. The inventive liquid formulation demonstrates high bioavailability consistent with approved dosage forms, low agglomeration, reduced content of excipients commonly used in solid oral dosage forms and extended shelf life stability. Also provided is a method of manufacturing a liquid quetiapine suspension composition for oral administration and methods of administering therapeutically effective dosages of an oral liquid quetiapine suspension composition to patients in need thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: March 9, 2021
    Assignee: TLC Therapeutics, LLC
    Inventors: Carl Tierney, Andrew Gardner, Jan Pick-Katolik, Stacey Powell, Mark Foley, Laurence Ramsey, Andrew Hardeman
  • Neuroactive steroids, compositions, and uses thereof
    Patent number: 10940156
    Abstract: Described herein are methods of treating a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression; and anxiety disorder, the method comprising administering to a human subject suffering from a disorder, e.g., tremor, e.g., essential tremor; depression, e.g., postpostum depression, an anxiety disorder with a neuroactive steroid or a composition comprising a neuroactive steroid (e.g., pregnanolone, allopregnanolone, alphadalone, ganaxolone, or alphaxolone).
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: March 9, 2021
    Assignee: Sage Therapeutics, Inc.
    Inventors: Stephen Jay Kanes, Helen Colquhoun
  • System for providing birth control
    Patent number: 10940157
    Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 9, 2021
    Assignee: The Population Council, Inc.
    Inventor: Bruce Variano
  • Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section
    Patent number: 10940158
    Abstract: The present invention relates to a composition comprising at least one human milk oligosaccharide and/or a precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants or young children born by C-section.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: March 9, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventor: Per Torp Sangild
  • Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
    Patent number: 10940159
    Abstract: A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: March 9, 2021
    Inventors: James Trinca Green, William Owen Wilkison
  • Biomarkers for predicting responsiveness to decitabine therapy
    Patent number: 10940160
    Abstract: Provided herein is technology relating to predicting a subject's resistance or responsiveness to a decitabine based therapy and particularly, but not exclusively, to methods, compositions, and related uses for predicting a subject's resistance or responsiveness to a decitabine based therapy wherein the subject is diagnosed with chronic myelomonocytic leukemia.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 9, 2021
    Assignee: The Regents of the University of Michigan
    Inventors: Maria Figueroa, Kirsten M. Plasseraud, Tingting Qin, Valeria Santini
  • Manipulation of EIF3 to modulate repeat associated non-ATG (RAN) translation
    Patent number: 10940161
    Abstract: Methods and compositions for modulating repeat non-ATG protein (RAN protein) translation are provided. In some aspects, the disclosure relates to methods for treating a subject having a disease associated with RAN protein translation by administering the subject a modulator of eIF3 or an eIF3 subunit, or an antibody that bind to a RAN protein.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: March 9, 2021
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Laura Ranum, Fatma Ayhan, Tao Zu
  • Use of polysaccharide for treating ST-elevation myocardial infarction and diseases of the digestion system
    Patent number: 10940162
    Abstract: Provided herein are methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using ?-1,3/1,6-D-glucan derived from mycelium extract of Ganoderma lucidum. Methods of treating ST-elevation myocardial infarction (STEMI) and diseases of the digestion system using a polysaccharide comprising ?-1,3/1,6-D-glucan are also provided.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 9, 2021
    Assignee: PT. Sahabat Lingkungan Hidup
    Inventors: Peter Sugita, Wiwiek Widyastuti Budiliantono, Aurelia Maxine Sugita
  • Bicarbonate as a potentiator for antimicrobial agents
    Patent number: 10940163
    Abstract: Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a microbial infection comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent. Also provided herein are methods of screening for antimicrobial compounds.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: March 9, 2021
    Assignee: McMaster University
    Inventors: Eric Brown, Maya Farha, Craig MacNair, Jonathan Stokes
  • Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
    Patent number: 10940164
    Abstract: The present invention relates to tolerogenic mammalian dendritic cells (iDCs) and methods for the production of tolerogenic DCs. In addition, the present invention provides methods for administration of tolerogenic dendritic cells as well as particles containing oligonucleotides to mammalian subjects. Enhanced tolerogenicity in a host can be useful for treating inflammatory and autoimmune related diseases, such as type 1 diabetes.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: March 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Nick Giannoukakis, Massimo M. Trucco
  • Adoptive T cell therapy
    Patent number: 10940165
    Abstract: The present disclosure provides a composition comprising isolated T cells, wherein the T cells have specificity against a range of clinical fungal pathogens.
    Type: Grant
    Filed: July 7, 2016
    Date of Patent: March 9, 2021
    Assignees: The University of Sydney, Western Sydney Local Health District, Westmead Institute for Medical Research, NSW Health Pathology
    Inventors: David Gottlieb, Leighton Clancy, Emily Blyth, Kenneth Paul Micklethwaite, Shivashni Deo
  • Bioassimilable protein-melanin complex, preparation and uses
    Patent number: 10940166
    Abstract: The present invention relates to a bioassimilable protein-melanin complex, advantageously soluble in water, comprising a protein extract, advantageously rich in S-sulfonated residues and melanin. The claimed complex further exhibits subsequent good assimilation in the human body. The invention also relates to a method for preparing the claimed bioassimilable protein-melanin complex, use of said complex and compositions containing at least said complex.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: March 9, 2021
    Inventor: Rosanna Carlini
  • Methods and uses of biological tissues for various stent and other medical applications
    Patent number: 10940167
    Abstract: Methods and uses of biological tissues for various stent and other medical applications. In an exemplary embodiment of a method of processing a tissue of the present disclosure, the method comprises the steps of acquiring a mammalian tissue comprising at least a portion of a pulmonary region tissue, selecting a sample of pulmonary region tissue from the at least a portion of a pulmonary region tissue, and fixing the sample of pulmonary region tissue using a fixative, resulting in a fixed sample. In at least one embodiment, the step of selecting a sample of pulmonary region tissue comprises selecting a sample of pulmonary ligament tissue from the mammalian tissue.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: March 9, 2021
    Assignee: CVDevices, LLC
    Inventors: Ghassan S. Kassab, Jose A. Navia, Sr., Jorge Jordana, Zachary C. Berwick
  • Method of treating Bruch's membrane hypofunction disease
    Patent number: 10940168
    Abstract: A composition includes a sea cucumber and ginseng/red ginseng composite extract which has the effect of regenerating the Bruch's membrane of the eye and improving the transport function of the Bruch's membrane. The composite composition improves the transport function of the Bruch's membrane and eliminates lipids accumulated on the membrane to promote the regeneration of the Bruch's membrane, thereby showing the effect of delaying or reversing the senescence process of the eye. Further, the composition is highly preventive or therapeutic of various diseases attributed to a decrease in the function of the Bruch's membrane with age, including age-related macular degeneration (AMD) and can solve the problem associated with the eye health maintenance of ordinary persons and with the transport reduction, resulting from senescence, of vitamins, metals, and anti-oxidative materials.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 9, 2021
    Assignee: ALTREGEN CO., LTD.
    Inventors: Yunhee Lee, Ali Hussain, Dae Bong Kim